Archive for the ‘U.S. Department Of Health And Human Services’ Category
Fuad el-Hibri, king of anthrax, wins an award from Ernst & Young
Marie-José Daoud
Awarded the Ernst and Young prize for Entrepreneur of the year 2009 in the Technology category for the Greater Washington region last June, Fuad El-Hibri is the CEO of Emergent Biosolutions, an American company that supplies the anthrax vaccine to the American government. He is in line for the national E&Y 2009 prize, which [...]
In: Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Management, Strategic National Stockpile, U.S. Department Of Health And Human Services, biotechnology · Tagged with: Emergent BioSolutions, Ernst & Young, Federal government of the United States, Food and Drug Administration, Porton Product, United States
Bad News Clouds Two Bio Defense Stocks
Written by Staff and Wire Reports
Tuesday, 08 December 2009 01:28
Key news developments will affect shares of these two companies who help meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons.
The two companies which waited until late after hours on Monday to announce [...]
In: Biothrax, Business, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Management, Shareholders, U.S. Department Of Health And Human Services · Tagged with: BARDA, Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, Federal government of the United States, Fuad El-Hibri, Strategic National Stockpile, United States, United States Department of Health and Human Services
Emergent BioSolutions reacts to BARDA’s Request for Proposal cancellation
by Nick Rees on December 8, 2009
Fuad El-Hibri
The Office of the Biomedical Advanced Research and Development Authority has advised Emergent BioSolutions that while BARDA’s Request for Proposal has been canceled, Emergent is encouraged to submit a proposal for the office’s Broad Agency Announcement.
BARDA canceled the RFP for the procurement for rPA vaccines after [...]
In: Board of directors, Chief executive officer, Clinical trial, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Leadership, Shareholders, U.S. Department Of Health And Human Services, biotechnology · Tagged with: Biotechnology and Pharmaceuticals, Chief executive officer, Emergent BioSolutions, U.S. Food and Drug Administration
EMERGENT BIOSOLUTIONS ANNOUNCES DR. STEPHEN LOCKHART JOINS COMPANY TO LEAD COMMERCIAL PRODUCT DEVELOPMENT SUBSIDIARY
Dr. Lockhart Brings Top-Tier Pharma Leadership to Development of Company’s Commercial Product Portfolio
ROCKVILLE, MD, October 18, 2007—Emergent BioSolutions Inc. (NYSE: EBS) announced today that Dr. Stephen Lockhart has been appointed President, Emergent Product Development UK. Dr. Lockhart will be based at the company’s office located in Wokingham, England, and his responsibilities will include providing [...]
In: Biothrax, Chief executive officer, Dr. Lockhart, Emergent BioSolutions, Fuad El-Hibri, U.S. Department Of Health And Human Services, U.S. Food and Drug Administration · Tagged with: Biotechnology and Pharmaceuticals, Business, Cambridge University, Clinical trial, Pharmaceuticals, Private Securities Litigation Reform Act, Royal College of Physicians, U.S. Food and Drug Administration
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES REMAINS COMMITTED TO PROCUREMENT OF BIOTHRAX® UNDER CURRENT CONTRACT
ROCKVILLE, MD, November 19, 2007 —Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Department of Health and Human Services (HHS) has reaffirmed its commitment to continue to purchase BioThrax® (Anthrax Vaccine Adsorbed) under the current contract for 18.75 million doses that provides for a firm fixed price of $400 million plus an additional $34 [...]
In: Biothrax, Chief executive officer, Clinical trial, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, U.S. Department Of Health And Human Services, U.S. Food and Drug Administration · Tagged with: Business, Chief executive officer, Clinical trial, Emergent BioSolutions, Infectious disease, Private Securities Litigation Reform Act, U.S. Food and Drug Administration, United States
Fuad El-Hibri From Wikipedia
Fuad El-Hibri (born March 2, 1958) is an American businessman, and CEO of Emergent BioSolutions http://en.wikipedia.org/wiki/Fuad_El-Hibri
Fuad El-Hibri (born March 2, 1958) in Hildesheim, Germany, spent his childhood equally in Europe and the Middle East before coming to the USA to get an economics degree from Stanford and an MBA from Yale.
Mr.El-Hibri earned a Masters Degree [...]
In: Biothrax, Board of directors, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, U.S. Department Of Health And Human Services · Tagged with: Board of directors, Booz Allen Hamilton, Mergers and acquisitions, Middle East, Saudi Arabia, Stanford University, United States, Yale University
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES REMAINS COMMITTED TO PROCUREMENT OF BIOTHRAX® UNDER CURRENT CONTRACT
ROCKVILLE, MD, November 19, 2007 —Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Department of Health and Human Services (HHS) has reaffirmed its commitment to continue to purchase BioThrax® (Anthrax Vaccine Adsorbed) under the current contract for 18.75 million doses that provides for a firm fixed price of $400 million plus an additional $34 [...]
In: Biothrax, Board of directors, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, U.S. Department Of Health And Human Services, U.S. Food and Drug Administration · Tagged with: Business, Chief executive officer, Clinical trial, Emergent BioSolutions, Infectious disease, Private Securities Litigation Reform Act, U.S. Food and Drug Administration, United States
Emergent Biosolutions Delivers Over 3 Million Doses Of Biothrax® To U.S. Department Of Health And Human Services For Strategic National Stockpile
Delivery represents approximately $75 million of revenue for 4Q 2006; Company on track to deliver remaining 1 million doses in 1Q 2007—
GAITHERSBURG, MD, December 14, 2006—Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has successfully completed the 4Q 2006 deliveries of over three million doses of BioThrax® (Anthrax Vaccine Adsorbed), the only FDA licensed [...]
In: Biothrax, Emergent BioSolutions, Fuad El-Hibri, Strategic National Stockpile, U.S. Department Of Health And Human Services